NOX — Noxopharm Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- AU$15.05m
- AU$19.33m
- AU$1.45m
Australia's Noxopharm up on promising results for pancreatic cancer drug candidate
Brief: Noxopharm To Prioritise Allocation Of Resources To Development Of Chromatm And Sofratm Program
Australia's Noxopharm rises on developing new mRNA 'vaccine enhancer' product
Brief: Noxopharm Announces New Proprietary Product Candidate Based On MRNA Technology
Brief: Noxopharm Posts HY Loss After Income Tax Expense Attributable A$5.4 Million
Brief: Noxopharm Says Its Pipeline Boosted By A$1.5M Grant To Hudson Institute Of Medical Research
Australia's Noxopharm climbs after dual-cell therapy shows positive results
Brief: Noxopharm Announces Results From Novel Dual-Cell Therapy Pancreatic Cancer Study
Brief: Noxopharm Says FY Loss Attributable A$18.7 Million Versus Loss A$9.3 Million
Brief: Noxopharm Says A$1.45M Granted To Hudson Institute Of Medical Research
Brief: Noxopharm Says Orphan Drug Designation Granted To Noxopharm By U.S. FDA
Australia's Noxopharm surges most in near 2 years after U.S FDA grant for cancer drug
Australia Stock Exchange release from NOXOPHARM : Orphan Drug Designation Granted to Noxopharm by US FDA
Australia Stock Exchange release from NOXOPHARM : PRE_NR Ends: 08:49:13
Australia Stock Exchange release from NOXOPHARM : First Patient Treated in CEP-2 Sarcoma Trial
Australia Stock Exchange release from NOXOPHARM : PRE_NR Ends: 08:54:06
Brief: Noxopharm Says HY Loss After Income Tax Expense Attributable A$8.6 Mln
Australia Stock Exchange release from NOXOPHARM : Appendix 4D and Half Year 2022 Financial Report
Australia Stock Exchange release from NOXOPHARM : PRE_NR Ends: 16:19:46